Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fezolinetant - Ogeda

Drug Profile

Fezolinetant - Ogeda

Alternative Names: A2693; AS3472693-00; ESN-364

Latest Information Update: 01 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Euroscreen
  • Developer Astellas Pharma; Ogeda
  • Class Antineoplastics; Fluorinated hydrocarbons; Ketones; Pyrazines; Small molecules; Thiadiazoles; Triazoles
  • Mechanism of Action Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hot flashes
  • Phase II Polycystic ovary syndrome; Uterine leiomyoma
  • No development reported Weight gain
  • Discontinued Benign prostatic hyperplasia; Endometriosis

Most Recent Events

  • 24 Jun 2022 Preregistration for Hot flashes in USA (PO)
  • 13 Jun 2022 Astellas Pharma completes a phase III Moonlight 3 trial in Hot flashes (PO) in China (NCT04451226)
  • 06 May 2022 Efficacy and adverse events data from a phase III SKYLIGHT 1 trial in severe vasomotor symptoms (hot flashes) associated with menopause released by Astellas
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top